ProCE Banner Activity

CE / CME

Expert Guidance on GLP-1 Receptor Agonists in Type 2 Diabetes: A Case-Based Approach

Multimedia
On-demand Webinar focusing on current best practices in leveraging GLP-1 RA therapy in T2D management.

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: December 04, 2020

Expiration: December 31, 2021

No longer available for credit.

Share

Faculty

Vanita R. Aroda

Vanita R. Aroda, MD

Director, Diabetes Clinical Research
Brigham and Women’s Hospital
Faculty
Harvard Medical School
Boston, Massachusetts

Arthi Thirumalai

Arthi Thirumalai, MBBS

Assistant Professor
Division of Metabolism, Endocrinology and Nutrition
University of Washington
Seattle, WA

Provided by

Provided by the Endocrine Society, in collaboration with Clinical Care Options.
ProCE Banner

Supporters

Supported by an educational grant from

Novo Nordisk Inc

Target Audience

This program is intended for endocrinologists (physicians and fellows), internists, primary care physicians, endocrine nurses, and other advanced practice professionals who care for patients with T2D.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recommendations from the latest ADA and AACE diabetes management guidelines regarding use of diabetes drugs in patients with high CV risk and/or renal disease
  • Consider the key clinical evidence from CV outcomes trials with GLP-1 RAs in management decisions for patients with T2D
  • Differentiate the pharmacokinetic/pharmacodynamic characteristics and side effect profiles of injection and oral GLP-1 RA products to optimize their use according to patient requirements and preferences

Faculty Disclosure

Primary Author

Vanita R. Aroda, MD

Director, Diabetes Clinical Research
Brigham and Women’s Hospital
Faculty
Harvard Medical School
Boston, Massachusetts

Vanita Aroda, MD, has disclosed that she has received consultant fees from Applied Therapeutics, Duke, Pfizer, Novo Nordisk, and Sanofi; funds for research support from Applied Therapeutics/Medpace, Lilly, Novo Nordisk, Premier/Fractyl, Sanofi/Medpace; and that her spouse is an employee at Janssen and Merck.

Arthi Thirumalai, MBBS

Assistant Professor
Division of Metabolism, Endocrinology and Nutrition
University of Washington
Seattle, WA

Arthi Thirumalai, MBBS, has disclosed that she has received funds for research support from Novo Nordisk.

Staff Disclosure

Staff

Anne Roc, PhD

Director, Scientific Services

Anne Roc, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by The Endocrine Society and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Additional Information

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the competence and performance of learners in leveraging the glycemic and extraglycemic properties of GLP-1 RA therapies to lower A1C, reduce comorbidity risks, and improve patient adherence and self-care in the management of T2D.